Related Experiment Video
Updated: Aug 12, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Prostaglandin E2 prevents disuse-induced cortical bone loss
1Division of Radiobiology, University of Utah School of Medicine, Salt Lake City 84112.
Bone
|January 1, 1992
Summary
Prostaglandin E2 (PGE2) prevents bone loss from disuse by increasing bone formation. This treatment counteracts immobilization-induced cortical bone loss and enhances bone structure.
Area of Science:
- Bone biology
- Skeletal physiology
- Pharmacology
Background:
- Disuse or immobilization leads to significant cortical bone loss.
- Understanding mechanisms to prevent disuse-induced bone loss is crucial for skeletal health.
Purpose of the Study:
- To determine if prostaglandin E2 (PGE2) can prevent disuse-induced cortical bone loss.
- To investigate PGE2's effect on adding bone mass to underloaded bones.
Main Methods:
- Adult female rats underwent hindlimb immobilization and received daily PGE2 doses (0-6 mg/kg/d) for 2-6 weeks.
- Histomorphometric analysis of tibial shaft sections assessed cortical bone changes.
- Evaluated effects on marrow cavity, intracortical porosity, and periosteal/corticoendosteal bone formation.
Main Results:
- Disuse increased marrow cavity and intracortical porosity, causing bone loss.
- PGE2 treatment enhanced periosteal and corticoendosteal bone formation.
- PGE2 counteracted disuse-induced bone loss by increasing bone formation, maintaining cortical bone percentage.
Conclusions:
- PGE2 administration effectively prevents immobilization-induced cortical bone loss.
- PGE2 stimulates bone formation, compensating for disuse-related bone resorption.
- PGE2 shows potential as a therapeutic agent for preventing bone loss due to inactivity.
Related Concept Videos
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...